Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04470024 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
A Phase 1 study of Cancer of the Head and Neck, sponsored by Providence Health & Services.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04470024 is a Phase 1 study of Cancer of the Head and Neck that is actively recruiting participants, run by Providence Health & Services. The registered enrollment target is 56 participants, above the 41-participant average among 3 other Cancer of the Head and Neck trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04470024, a Phase 1 study of Cancer of the Head and Neck, is actively recruiting participants, sponsored by Providence Health & Services.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
Conditions Studied
Interventions
- DRUG INCAGN01876
- DRUG INCMGA00012
- BIOLOGICAL DPV-001
Study Locations (1)
Oregon
- Portland Providence Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-08-05 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04470024
The ClinicalTrials.gov registry entry for NCT04470024 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 41-participant average among 3 other Cancer of the Head and Neck trials with a reported enrollment target (37% higher). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer of the Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which INCAGN01876 is the first listed.
NCT04470024 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT04470024 about?
NCT04470024 is a clinical study titled "Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC". This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
What is the current status of trial NCT04470024?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2021-08-05. Estimated completion is 2027-12-31.
What conditions does trial NCT04470024 study?
This clinical trial studies the following conditions: Cancer of the Head and Neck.
What interventions are being tested in trial NCT04470024?
The interventions under investigation include: INCAGN01876 (DRUG), INCMGA00012 (DRUG), DPV-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04470024?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04470024 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer of the Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
RECRUITING · Phase 2
-
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.